Orlistat Market Overview

Global Orlistat Market was valued at USD 3.02 billion in 2021 and is expected to reach USD 4.61 billion by the year 2028, at a CAGR of 6.2%.

The growing number of weight-loss awareness initiatives is likely to be a significant driver for the growth of Orlistat market. Mainly, orlistat is used as an anti-obesity medication. The primary function of Orlistat is to inhibit fat absorption from the human diet. It limits fat absorption by acting as a lipase inhibitor, resulting in a reduction in calorie intake. Orlistat works by blocking pancreatic and gastric lipases, which are enzymes in the gut that break down triglycerides. When lipase activity is inhibited, dietary triglycerides are not digested into absorbable-free fatty acids and instead stay unaltered.

In most of the regions across globe, obesity-related issues have been a growing concern in the recent years. Orlistat also lowers blood pressure and inhibits the formation of type 2 diabetes in obese population. Orlistat medication does not allow an individual to regain lost weight and does not block the absorption of fats from non-fat foods and sugar.

Major Growth Drivers: Orlistat Market

Over the forecasted period, a robust pipeline of the orlistat drug is projected to enhance market growth. Furthermore, Orlistat, developed by the University of Texas South Western Medical Center, has been in phase 2 testing since 2015. Orlistat is a medication used to treat type 1 hyperlipoproteinemia. Lipoprotein lipase deficiency causes hyperlipoproteinemia type 1. The University of Texas South Western Medical Canters’ SLx-4090 is under phase 2 testing to see how well it works in conjunction with Orlistat. SLx-4090 is used to treat elevated blood fat levels, which are most commonly seen in people with hyperlipoproteinemia type 1.

The rising prevalence of obesity and its related diseases is projected to drive orlistat market expansion. According to a National Family Health Survey done in 2015 in India, over 9.8 million men and over 20 million women are obese. India has the world's second-highest rate of obese children, with the number steadily growing by 3-5 million patients per year.

Challenges : Orlistat Market

Health risks such as the risk of psychiatric disorder and stroke are expected to have a negative impact on market growth over the forecast period. Innumerable anti-obesity drugs approved in the last decade, including Knoll and Acomplia (rimonabant), have been withdrawn due to long-term side effects such as suicidal thoughts, depression, and cardiovascular problems. Due to the previously mentioned factors, healthcare providers have a negative impression of anti-obesity drugs and do not recommend them to consumers.

The market for orlistat and anti-obesity drugs is expected to grow slowly due to high attrition rates in the recent years. The transition of therapeutic goods from phase one through market is difficult because more than 80% of drugs are discontinued before reaching pre-registration. It will result in a low number of representative drugs in later stages of development.

Market Segmentation

Geographically, Asia-Pacific accounted for the largest market share in 2017 and is anticipated to maintain its dominance by the end of 2023. Asia-Pacific is expected to exhibit the highest CAGR of 6.3% over the forecast period.

Players Covered in Orlistat Market are :

• Roche
• GSK group
• Teva
• Sandoz(Novartis)
• STADA-VN J.V.Co. Ltd
• Hexal AG
• National Company for Pharmaceutical Industry
• Lunan Pharmaceutical Group Corporation
• ZEIN pharmaceutical
• HISUN
• Taj Pharmaceuticals Ltd
• Kabir Life Sciences & Research
• DM Pharma
• China Zhongshan Pharm and other major players.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Type
 3.2 By Distribution Channel

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Orlistat Market by Type
 5.1 Orlistat Market Overview Snapshot and Growth Engine
 5.2 Orlistat Market Overview
 5.3 120 mg
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 120 mg: Grographic Segmentation
 5.4 60 mg
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 60 mg: Grographic Segmentation

Chapter 6: Orlistat Market by Distribution Channel
 6.1 Orlistat Market Overview Snapshot and Growth Engine
 6.2 Orlistat Market Overview
 6.3 Hospital Pharmacies
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Hospital Pharmacies: Grographic Segmentation
 6.4 Online Pharmacies
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Online Pharmacies: Grographic Segmentation
 6.5 Retail Pharmacies
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Retail Pharmacies: Grographic Segmentation

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Positioning
  7.1.2 Orlistat Sales and Market Share By Players
  7.1.3 Industry BCG Matrix
  7.1.4 Ansoff Matrix
  7.1.5 Orlistat Industry Concentration Ratio (CR5 and HHI)
  7.1.6 Top 5 Orlistat Players Market Share
  7.1.7 Mergers and Acquisitions
  7.1.8 Business Strategies By Top Players
 7.2 ROCHE
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Operating Business Segments
  7.2.5 Product Portfolio
  7.2.6 Business Performance
  7.2.7 Key Strategic Moves and Recent Developments
  7.2.8 SWOT Analysis
 7.3 GSK GROUP
 7.4 TEVA
 7.5 SANDOZ(NOVARTIS)
 7.6 STADA-VN J.V.CO. LTD
 7.7 HEXAL AG
 7.8 NATIONAL COMPANY FOR PHARMACEUTICAL INDUSTRY
 7.9 LUNAN PHARMACEUTICAL GROUP CORPORATION
 7.10 ZEIN PHARMACEUTICAL
 7.11 HISUN
 7.12 TAJ PHARMACEUTICALS LTD
 7.13 KABIR LIFE SCIENCES & RESEARCH
 7.14 DM PHARMA
 7.15 CHINA ZHONGSHAN PHARM
 7.16 OTHER MAJOR PLAYERS

Chapter 8: Global Orlistat Market Analysis, Insights and Forecast, 2016-2028
 8.1 Market Overview
 8.2 Historic and Forecasted Market Size By Type
  8.2.1 120 mg
  8.2.2 60 mg
 8.3 Historic and Forecasted Market Size By Distribution Channel
  8.3.1 Hospital Pharmacies
  8.3.2 Online Pharmacies
  8.3.3 Retail Pharmacies

Chapter 9: North America Orlistat Market Analysis, Insights and Forecast, 2016-2028
 9.1 Key Market Trends, Growth Factors and Opportunities
 9.2 Impact of Covid-19
 9.3 Key Players
 9.4 Key Market Trends, Growth Factors and Opportunities
 9.4 Historic and Forecasted Market Size By Type
  9.4.1 120 mg
  9.4.2 60 mg
 9.5 Historic and Forecasted Market Size By Distribution Channel
  9.5.1 Hospital Pharmacies
  9.5.2 Online Pharmacies
  9.5.3 Retail Pharmacies
 9.6 Historic and Forecast Market Size by Country
  9.6.1 U.S.
  9.6.2 Canada
  9.6.3 Mexico

Chapter 10: Europe Orlistat Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Type
  10.4.1 120 mg
  10.4.2 60 mg
 10.5 Historic and Forecasted Market Size By Distribution Channel
  10.5.1 Hospital Pharmacies
  10.5.2 Online Pharmacies
  10.5.3 Retail Pharmacies
 10.6 Historic and Forecast Market Size by Country
  10.6.1 Germany
  10.6.2 U.K.
  10.6.3 France
  10.6.4 Italy
  10.6.5 Russia
  10.6.6 Spain
  10.6.7 Rest of Europe

Chapter 11: Asia-Pacific Orlistat Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Type
  11.4.1 120 mg
  11.4.2 60 mg
 11.5 Historic and Forecasted Market Size By Distribution Channel
  11.5.1 Hospital Pharmacies
  11.5.2 Online Pharmacies
  11.5.3 Retail Pharmacies
 11.6 Historic and Forecast Market Size by Country
  11.6.1 China
  11.6.2 India
  11.6.3 Japan
  11.6.4 Singapore
  11.6.5 Australia
  11.6.6 New Zealand
  11.6.7 Rest of APAC

Chapter 12: Middle East & Africa Orlistat Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Type
  12.4.1 120 mg
  12.4.2 60 mg
 12.5 Historic and Forecasted Market Size By Distribution Channel
  12.5.1 Hospital Pharmacies
  12.5.2 Online Pharmacies
  12.5.3 Retail Pharmacies
 12.6 Historic and Forecast Market Size by Country
  12.6.1 Turkey
  12.6.2 Saudi Arabia
  12.6.3 Iran
  12.6.4 UAE
  12.6.5 Africa
  12.6.6 Rest of MEA

Chapter 13: South America Orlistat Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Type
  13.4.1 120 mg
  13.4.2 60 mg
 13.5 Historic and Forecasted Market Size By Distribution Channel
  13.5.1 Hospital Pharmacies
  13.5.2 Online Pharmacies
  13.5.3 Retail Pharmacies
 13.6 Historic and Forecast Market Size by Country
  13.6.1 Brazil
  13.6.2 Argentina
  13.6.3 Rest of SA

Chapter 14 Investment Analysis

Chapter 15 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. ORLISTAT MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. ORLISTAT MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. ORLISTAT MARKET COMPETITIVE RIVALRY
TABLE 005. ORLISTAT MARKET THREAT OF NEW ENTRANTS
TABLE 006. ORLISTAT MARKET THREAT OF SUBSTITUTES
TABLE 007. ORLISTAT MARKET BY TYPE
TABLE 008. 120 MG MARKET OVERVIEW (2016-2028)
TABLE 009. 60 MG MARKET OVERVIEW (2016-2028)
TABLE 010. ORLISTAT MARKET BY DISTRIBUTION CHANNEL
TABLE 011. HOSPITAL PHARMACIES MARKET OVERVIEW (2016-2028)
TABLE 012. ONLINE PHARMACIES MARKET OVERVIEW (2016-2028)
TABLE 013. RETAIL PHARMACIES MARKET OVERVIEW (2016-2028)
TABLE 014. NORTH AMERICA ORLISTAT MARKET, BY TYPE (2016-2028)
TABLE 015. NORTH AMERICA ORLISTAT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 016. N ORLISTAT MARKET, BY COUNTRY (2016-2028)
TABLE 017. EUROPE ORLISTAT MARKET, BY TYPE (2016-2028)
TABLE 018. EUROPE ORLISTAT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 019. ORLISTAT MARKET, BY COUNTRY (2016-2028)
TABLE 020. ASIA PACIFIC ORLISTAT MARKET, BY TYPE (2016-2028)
TABLE 021. ASIA PACIFIC ORLISTAT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 022. ORLISTAT MARKET, BY COUNTRY (2016-2028)
TABLE 023. MIDDLE EAST & AFRICA ORLISTAT MARKET, BY TYPE (2016-2028)
TABLE 024. MIDDLE EAST & AFRICA ORLISTAT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 025. ORLISTAT MARKET, BY COUNTRY (2016-2028)
TABLE 026. SOUTH AMERICA ORLISTAT MARKET, BY TYPE (2016-2028)
TABLE 027. SOUTH AMERICA ORLISTAT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 028. ORLISTAT MARKET, BY COUNTRY (2016-2028)
TABLE 029. ROCHE: SNAPSHOT
TABLE 030. ROCHE: BUSINESS PERFORMANCE
TABLE 031. ROCHE: PRODUCT PORTFOLIO
TABLE 032. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 032. GSK GROUP: SNAPSHOT
TABLE 033. GSK GROUP: BUSINESS PERFORMANCE
TABLE 034. GSK GROUP: PRODUCT PORTFOLIO
TABLE 035. GSK GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 035. TEVA: SNAPSHOT
TABLE 036. TEVA: BUSINESS PERFORMANCE
TABLE 037. TEVA: PRODUCT PORTFOLIO
TABLE 038. TEVA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 038. SANDOZ(NOVARTIS): SNAPSHOT
TABLE 039. SANDOZ(NOVARTIS): BUSINESS PERFORMANCE
TABLE 040. SANDOZ(NOVARTIS): PRODUCT PORTFOLIO
TABLE 041. SANDOZ(NOVARTIS): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 041. STADA-VN J.V.CO. LTD: SNAPSHOT
TABLE 042. STADA-VN J.V.CO. LTD: BUSINESS PERFORMANCE
TABLE 043. STADA-VN J.V.CO. LTD: PRODUCT PORTFOLIO
TABLE 044. STADA-VN J.V.CO. LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 044. HEXAL AG: SNAPSHOT
TABLE 045. HEXAL AG: BUSINESS PERFORMANCE
TABLE 046. HEXAL AG: PRODUCT PORTFOLIO
TABLE 047. HEXAL AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. NATIONAL COMPANY FOR PHARMACEUTICAL INDUSTRY: SNAPSHOT
TABLE 048. NATIONAL COMPANY FOR PHARMACEUTICAL INDUSTRY: BUSINESS PERFORMANCE
TABLE 049. NATIONAL COMPANY FOR PHARMACEUTICAL INDUSTRY: PRODUCT PORTFOLIO
TABLE 050. NATIONAL COMPANY FOR PHARMACEUTICAL INDUSTRY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. LUNAN PHARMACEUTICAL GROUP CORPORATION: SNAPSHOT
TABLE 051. LUNAN PHARMACEUTICAL GROUP CORPORATION: BUSINESS PERFORMANCE
TABLE 052. LUNAN PHARMACEUTICAL GROUP CORPORATION: PRODUCT PORTFOLIO
TABLE 053. LUNAN PHARMACEUTICAL GROUP CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. ZEIN PHARMACEUTICAL: SNAPSHOT
TABLE 054. ZEIN PHARMACEUTICAL: BUSINESS PERFORMANCE
TABLE 055. ZEIN PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 056. ZEIN PHARMACEUTICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. HISUN: SNAPSHOT
TABLE 057. HISUN: BUSINESS PERFORMANCE
TABLE 058. HISUN: PRODUCT PORTFOLIO
TABLE 059. HISUN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. TAJ PHARMACEUTICALS LTD: SNAPSHOT
TABLE 060. TAJ PHARMACEUTICALS LTD: BUSINESS PERFORMANCE
TABLE 061. TAJ PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
TABLE 062. TAJ PHARMACEUTICALS LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. KABIR LIFE SCIENCES & RESEARCH: SNAPSHOT
TABLE 063. KABIR LIFE SCIENCES & RESEARCH: BUSINESS PERFORMANCE
TABLE 064. KABIR LIFE SCIENCES & RESEARCH: PRODUCT PORTFOLIO
TABLE 065. KABIR LIFE SCIENCES & RESEARCH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. DM PHARMA: SNAPSHOT
TABLE 066. DM PHARMA: BUSINESS PERFORMANCE
TABLE 067. DM PHARMA: PRODUCT PORTFOLIO
TABLE 068. DM PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. CHINA ZHONGSHAN PHARM: SNAPSHOT
TABLE 069. CHINA ZHONGSHAN PHARM: BUSINESS PERFORMANCE
TABLE 070. CHINA ZHONGSHAN PHARM: PRODUCT PORTFOLIO
TABLE 071. CHINA ZHONGSHAN PHARM: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 072. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 073. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 074. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. ORLISTAT MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. ORLISTAT MARKET OVERVIEW BY TYPE
FIGURE 012. 120 MG MARKET OVERVIEW (2016-2028)
FIGURE 013. 60 MG MARKET OVERVIEW (2016-2028)
FIGURE 014. ORLISTAT MARKET OVERVIEW BY DISTRIBUTION CHANNEL
FIGURE 015. HOSPITAL PHARMACIES MARKET OVERVIEW (2016-2028)
FIGURE 016. ONLINE PHARMACIES MARKET OVERVIEW (2016-2028)
FIGURE 017. RETAIL PHARMACIES MARKET OVERVIEW (2016-2028)
FIGURE 018. NORTH AMERICA ORLISTAT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 019. EUROPE ORLISTAT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. ASIA PACIFIC ORLISTAT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. MIDDLE EAST & AFRICA ORLISTAT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. SOUTH AMERICA ORLISTAT MARKET OVERVIEW BY COUNTRY (2016-2028)